An interventional study of Positive Affect Treatment and Negative Affect Treatment in Depression and Anxiety, sponsored by University of California, Los Angeles. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-12.
Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Depression by University of California, Los Angeles — 12 open to participants now, 12 under way, none of them phase 3. Depression · University of California, Los Angeles.
Among the 81 studies in Depression by University of California, Los Angeles, this one is the 34th largest by enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2019, is one of 45 with no phase, and was the 43rd registered.
8,582 studies on the registry are indexed under Depression; 1,723 are open to participants now.
Browse Depression studies →12 of the 81 studies in Depression by University of California, Los Angeles are open now, in 1 country. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 50–95
University of California, Los Angeles · Sites in United States
Ages 18+ · Women only
University of California, Los Angeles · Sites in United States
Ages 18+ · Women only · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
University of California, Los Angeles · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 1,089 Depression studies recruiting now, 470 (43%) set no upper age limit and 519 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 7 · Phase 3 1 · Phase 4 14
First in 2001; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 85 is close to the median of 81 across 7,066 interventional studies indexed under Depression.
Median enrollment 76 across the 74 interventional studies, 1,490 across the 5 observational. Of the 64 that completed or were terminated, 14 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, Los Angeles is the lead sponsor of 1,170 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
3 of the studies in Depression by University of California, Los Angeles that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05591937University of California, Los AngelesS.T.A.N.D. Alacrity Center Signature Project | 2027-04-30 |
| NCT07577947University of California, Los AngelesHealth And Response: Digital Markers for Outcomes in Perinatal Depression Treatment Study | 2027-05-01 |
| NCT07219875University of California, Los AngelesTraining Reward Responsiveness Through Virtual Reality | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 81 studies in Depression by University of California, Los Angeles, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and targets of Positive Affect Treatment, a psychotherapy specifically aimed at enhancing reward sensitivity in individuals with low positive affect (a core feature of anhedonia) in the context of depression or anxiety.
Target enrollment is 68 male and female participants with low positive affect and depression or anxiety and impaired functioning, between the ages of 18 and 65 years, who will be randomized to either Positive Affect Treatment or Negative Affect Treatment (designed to reduce threat sensitivity). Participants will complete laboratory tests, psychiatric assessments, and self-report questionnaires as part of the study.
The total length of participation is around 4 months.
Low positive affect in the context of depression or anxiety has been relatively resistant to pharmacological and psychological treatments. Newer treatments that focus upon positivity or reward sensitivity have shown promising results.
As an NIMH funded R61 phase trial, the purpose of the current randomized controlled trial is to evaluate the efficacy and targets of Positive Affect Treatment (designed to augment reward sensitivity) for individuals with low positive affect in the context of depression or anxiety symptoms. Targets include behavioral, cognitive, physiological and experiential measures of three reward processes: reward anticipation, response to reward attainment, and reward learning. Specificity of target engagement is assessed by comparison with Negative Affect Treatment, designed to reduce threat sensitivity.
Clinical outcomes are assessed at baseline and either weekly or at Week 5, Week 10, and Week 15 (post). Targets are assessed at baseline, Week 5, Week 10, and Week 15. Statistical models evaluate whether change in outcomes and change in target measures are greater as a result of Positive Affect Treatment compared to Negative Affect Treatment and whether changes in target measures correlate with changes in outcome measures.
Target enrollment is 68 male and female participants with low positive affect and depression or anxiety and impaired functioning between the ages of 18 and 65 who will be randomized to Positive Affect Treatment or Negative Affect Treatment, each comprising 15 individual psychotherapy sessions.
Participants will complete laboratory tests and psychiatric assessments and self-report questionnaires as part of the study. Total length of participation is around 4 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
15 sessions of psychotherapy designed to augment reward anticipation, reward attainment, and reward learning.
Behavioral: Positive Affect Treatment
15 sessions of psychotherapy designed to decrease threat avoidance, threat appraisal and arousal.
Behavioral: Negative Affect Treatment
Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
Positive Affect Subscale of the Positive and Negative Affect Scale (PANAS-P)
Reported positive affect. Scores can range from 10-50, with higher scores representing higher levels of positive affect.
Time frame: Week 0, Week 5, Week 10, Week 16
Interviewer Anhedonia Ratings
Interviewer ratings of interest, pleasure, and motivation in hobbies/pastimes, foods/drinks, social activities (score range: 1-12), higher scores indicate lower anhedonia.
Time frame: Week 0, Week 5, Week 10, Week 16
Depression Anxiety and Stress Scale (DASS-21)
Reported symptoms of depression, anxiety, and stress (score range: 0-63), higher scores indicate higher symptom severity and frequency.
Time frame: Week 0, Week 5, Week 10, Week 16
Sheehan Disability Scale (SDS)
Reported impairment due to symptoms (score range: 0-30) with higher scores indicating greater impairment. Includes reported number of days of missed school/work and number of days of reduced productivity. Statistical analyses have not yet been conducted for this outcome measure.
Time frame: Week 0, Week 5, Week 10, Week 16
Beck Depression Inventory (BDI)
Reported suicidal ideation (item 9 on the BDI), scores range from 0-3 with higher scores indicating a higher degree of suicidal ideation. Statistical analyses have not yet been conducted for this outcome measure.
Time frame: Week 0, Week 5, Week 10, Week 16
Daily Activity/Social Interaction (Actigraph)
We intended to collect data on energy expenditure over four 7-day periods (at week 0, week 5, week 10, and week 16) using a wrist-worn Actigraph tri-axial accelerometer. However, the use of Actigraph monitors was terminated early in the study due to the onset of the COVID-19 pandemic.
Time frame: Week 0, Week 5, Week 10, Week 16
Effort Expenditure for Rewards Task (EEfRT)
The Effort Expenditure for Rewards Task (EEfRT) is a computer-based multi-trial task used to objectively assess decision-making and willingness to expend effort for reward. The dependent variable is the ratio of hard (high-effort) choices to the total number of trials. Results range from 0 to 1, with higher values indicating a higher proportion of hard (high-effort) choices. Results show the mean proportion of high-effort choices.
Time frame: Week 0, Week 5, Week 10, Week 16
Monetary Incentive Task
Heart rate acceleration during the Monetary Incentive Task (MIT) was used to measure cardiac responding to the prospect of a monetary reward. The dependent variable is the interbeat interval acceleration during the task (score range in our sample: -0.16 to 0.17). Higher values indicate greater cardiac responding to the prospect of monetary reward.
Time frame: Week 0, Week 5, Week 10, Week 16
Behavioral Inhibition/Behavioral Activation (Reward Drive Subscale) (BAS-RD)
Mediator: Reported reward sensitivity (score range: 4-16), with higher scores indicating higher sensitivity
Time frame: Week 0, Week 5, Week 10, Week 16
Dimensional Anhedonia Rating Scale-Anticipation and Motivation Items
Mediator: Reported reward desire, motivation, and effort (score range: 0-76) with higher scores indicating higher degree of reward desire, motivation, and effort.
Time frame: Week 0, Week 5, Week 10, Week 16
Dimensional Anhedonia Rating Scale-Consummatory Items
Mediator: Reported reward-related pleasure (score range: 0-28), with higher scores indicating higher degree of pleasure.
Time frame: Week 0, Week 5, Week 10, Week 16
Modified Attentional Dot Probe Task-Disengagement Bias for Negative Stimuli
The Modified Attentional Dot Probe Task is a computer-based multi-trial task used to objectively assess attentional bias toward positively- and negatively-valenced stimuli. The dependent variable is the reaction time index for disengagement bias from sad faces. This is calculated as follows: (Cue appears proximal to emotional face in the pair of emotional face and random blur image: reaction time for target distal to emotional face minus reaction time for target proximal to emotional face) minus (Cue proximal to neutral face in pair of neutral face and random blur image: reaction time for target distal to neutral face minus reaction time for target proximal to neutral face). The range of values in our sample was: -309.28 to 283.45.
Time frame: Week 0, Week 5, Week 10, Week 16
Modified Attentional Dot Probe Task-Engagement Bias for Positive Stimuli
The Modified Attentional Dot Probe Task is a computer-based multi-trial task used to objectively assess attentional bias toward positively- and negatively-valenced stimuli. The dependent variable is the reaction time index for engagement bias from happy faces. This is calculated as follows: (Cue probe distal to negative image in negative/abstract image pair: RT for target probe distal to negative image minus RT for target probe proximal to negative image) minus (Cue probe distal to neutral image in neutral/abstract image pair: RT for target probe distal to neutral image minus RT for target probe proximal to neutral image). The range of data in our sample was: -237.82 to to 343.93. Statistical analyses have not yet been conducted for this outcome measure.
Time frame: Week 0, Week 5, Week 10, Week 16
International Affective Picture System Task
Heart rate acceleration during presentation of images from the International Affective Picture Systems (IAPS) was used to assess cardiac responding to positive images. The dependent variable is heart rate acceleration during the 6 seconds of positive image presentation relative to the last 2 seconds before picture onset. Higher values indicate greater cardiac responding to positive images. The range of values in our sample was: -0.12 to 0.09.
Time frame: Week 0, Week 5, Week 10, Week 16
Temporal Experience of Pleasure Scale (Consummatory Subscale)
Mediator: Reported reward consummatory pleasure (score range: 8-48), with higher scores indicating higher reported reward consummatory pleasure
Time frame: Week 0, Week 5, Week 10, Week 16
Probabilistic Reward Task (PRT)
The Probabilistic Reward Task (PRT) is a computer-based multi-trial task used to objectively assess the propensity to modulate behavior as a function of prior reinforcements. The dependent variable is response bias (measured as accuracy) toward the more frequently rewarded stimulus. A high response bias emerges when subjects show high rates of correct identification (hits) for the rich stimulus and high miss rates for the lean stimulus (i.e., the stimulus associated with less frequent rewards). Higher values indicate a greater propensity to modulate behavior as a function of prior reinforcements. The range of values in our sample was: -0.58 to 0.78.
Time frame: Week 0, Week 5, Week 10, Week 16
Pavlovian Instrumental Transfer Task - Force (PIT-FORCE)
The Pavlovian Instrumental Transfer (PIT) task assesses the extent to which a conditional stimulus paired with reward influences instrumental responding to gain rewards. The dependent variable was handgrip force exerted in response to stimuli during a test phase following Pavlovian conditioning. Higher values indicate greater instrumental responding to gain rewards as a function of Pavlovian conditioning to a conditional stimulus paired with reward. The range of values in our sample was: -18.76 to 61.30.
Time frame: Week 0, Week 5, Week 10, Week 16
Pavlovian Instrumental Transfer Task - Valence (PIT-VALENCE)
Within the Pavlovian Instrumental Transfer Task (PIT), participants rate the pleasantness (0-4) for three conditional stimuli to indicate the perceived value of reward associated with each one. The dependent variable is the self-reported pleasantness for rewarded stimuli compared to nonrewarded stimuli. This is calculated by first taking the average of participants' pleasantness ratings for the three CS+s and CS-s, and then subtracting the average CS- ratings from the average CS+ ratings. Higher values indicate greater responding to Pavlovian conditioning during the task.
Time frame: Week 0, Week 5, Week 10, Week 16
Recruitment began February 23, 2019 and ended February 5, 2021. A brief study description was distributed via lab websites, social media, ClinicalTrials.gov, and campus and local area flyers.
| Milestone | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Started | 42 | 43 |
| Week 5 assessment | 36 | 37 |
| Week 10 assessment | 32 | 29 |
| Completed | 31 | 26 |
| Not completed | 11 | 17 |
| Withdrew: Withdrawal by subject | 11 | 17 |
Reported positive affect. Scores can range from 10-50, with higher scores representing higher levels of positive affect.
| score on a scale | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 20.76 ± 7.42 | 29.42 ± 4.74 |
| Week 5 | 24.18 ± 7.37 | 19.42 ± 8.12 |
| Week 10 | 26.88 ± 8.29 | 22.57 ± 9.82 |
| Week 16 | 27.30 ± 7.23 | 23.85 ± 9.28 |
Interviewer ratings of interest, pleasure, and motivation in hobbies/pastimes, foods/drinks, social activities (score range: 1-12), higher scores indicate lower anhedonia.
| score on a scale | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 7.66 ± 2.13 | 7.47 ± 1.80 |
| Week 5 | 6.11 ± 2.26 | 5.49 ± 2.40 |
| Week 10 | 4.91 ± 2.19 | 4.93 ± 2.40 |
| Week 16 | 4.19 ± 1.47 | 4.43 ± 2.23 |
Reported symptoms of depression, anxiety, and stress (score range: 0-63), higher scores indicate higher symptom severity and frequency.
| score on a scale | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 27.36 ± 11.27 | 24.51 ± 10.54 |
| Week 5 | 17.90 ± 11.56 | 17.92 ± 10.51 |
| Week 10 | 11.55 ± 9.60 | 13.00 ± 12.13 |
| Week 16 | 9.09 ± 6.85 | 12.38 ± 10.90 |
Reported impairment due to symptoms (score range: 0-30) with higher scores indicating greater impairment. Includes reported number of days of missed school/work and number of days of reduced productivity. Statistical analyses have not yet been conducted for this outcome measure.
| score on a scale | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 18.40 ± 6.14 | 16.65 ± 6.51 |
| Week 5 | 14.53 ± 6.46 | 14.84 ± 6.97 |
| Week 10 | 11.19 ± 6.34 | 11.86 ± 6.94 |
| Week 16 | 9.56 ± 6.64 | 9.08 ± 6.38 |
Reported suicidal ideation (item 9 on the BDI), scores range from 0-3 with higher scores indicating a higher degree of suicidal ideation. Statistical analyses have not yet been conducted for this outcome measure.
| score on a scale | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 0.17 ± 0.38 | 0.23 ± 0.43 |
| Week 5 | 0.18 ± 0.39 | 0.14 ± 0.35 |
| Week 10 | 0.18 ± 0.39 | 0.20 ± 0.41 |
| Week 16 | 0.23 ± 0.43 | 0.08 ± 0.27 |
We intended to collect data on energy expenditure over four 7-day periods (at week 0, week 5, week 10, and week 16) using a wrist-worn Actigraph tri-axial accelerometer. However, the use of Actigraph monitors was terminated early in the study due to the onset of the COVID-19 pandemic.
| kcals expended per hour | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 40.212 ± 19.677 | 34.634 ± 24.427 |
| Week 5 | 41.98 ± 20.58 | 41.44 ± 26.06 |
| Week 10 | 34.21 ± 20.75 | 46.92 ± 29.33 |
| Week 16 | 43.69 ± 27.13 | 56.57 ± 53.04 |
The Effort Expenditure for Rewards Task (EEfRT) is a computer-based multi-trial task used to objectively assess decision-making and willingness to expend effort for reward. The dependent variable is the ratio of hard (high-effort) choices to the total number of trials. Results range from 0 to 1, with higher values indicating a higher proportion of hard (high-effort) choices. Results show the mean proportion of high-effort choices.
| proportion of high effort choices | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 0.41 ± 0.20 | 0.41 ± 0.27 |
| Week 5 | 0.43 ± 0.22 | 0.39 ± 0.23 |
| Week 10 | 0.51 ± 0.26 | 0.41 ± 0.31 |
| Week 16 | 0.48 ± 0.29 | 0.42 ± 0.32 |
Heart rate acceleration during the Monetary Incentive Task (MIT) was used to measure cardiac responding to the prospect of a monetary reward. The dependent variable is the interbeat interval acceleration during the task (score range in our sample: -0.16 to 0.17). Higher values indicate greater cardiac responding to the prospect of monetary reward.
| beats/ms^2 | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | -0.012 ± 0.512 | -0.017 ± 0.046 |
| Week 5 | 0.017 ± 0.048 | 0.013 ± 0.061 |
| Week 10 | -0.002 ± 0.042 | 0.004 ± 0.043 |
| Week 16 | 0.003 ± 0.026 | 0.026 ± 0.053 |
Mediator: Reported reward sensitivity (score range: 4-16), with higher scores indicating higher sensitivity
| score on a scale | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 9.67 ± 2.63 | 9.42 ± 2.21 |
| Week 5 | 10.50 ± 2.63 | 10.14 ± 2.26 |
| Week 10 | 10.66 ± 2.51 | 10.66 ± 2.36 |
| Week 16 | 10.30 ± 2.56 | 11.08 ± 1.96 |
Mediator: Reported reward desire, motivation, and effort (score range: 0-76) with higher scores indicating higher degree of reward desire, motivation, and effort.
| score on a scale | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 42.85 ± 16.96 | 49.16 ± 16.32 |
| Week 5 | 52.28 ± 14.20 | 52.46 ± 15.36 |
| Week 10 | 55.63 ± 15.69 | 55.66 ± 16.08 |
| Week 16 | 59.84 ± 14.31 | 58.46 ± 16.31 |
Mediator: Reported reward-related pleasure (score range: 0-28), with higher scores indicating higher degree of pleasure.
| score on a scale | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 17.56 ± 6.26 | 19.12 ± 6.16 |
| Week 5 | 20.39 ± 4.76 | 20.51 ± 6.25 |
| Week 10 | 21.50 ± 5.66 | 21.59 ± 5.99 |
| Week 16 | 22.88 ± 4.73 | 22.12 ± 5.78 |
The Modified Attentional Dot Probe Task is a computer-based multi-trial task used to objectively assess attentional bias toward positively- and negatively-valenced stimuli. The dependent variable is the reaction time index for disengagement bias from sad faces. This is calculated as follows: (Cue appears proximal to emotional face in the pair of emotional face and random blur image: reaction time for target distal to emotional face minus reaction time for target proximal to emotional face) minus (Cue proximal to neutral face in pair of neutral face and random blur image: reaction time for target distal to neutral face minus reaction time for target proximal to neutral face). The range of values in our sample was: -309.28 to 283.45.
| milliseconds (ms) | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | -43.43 ± 114.62 | 2.80 ± 105.63 |
| Week 5 | 16.70 ± 98.11 | -16.49 ± 102.44 |
| Week 10 | -3.07 ± 82.01 | -31.56 ± 94.05 |
| Week 16 | 4.85 ± 97.00 | 66.24 ± 101.47 |
The Modified Attentional Dot Probe Task is a computer-based multi-trial task used to objectively assess attentional bias toward positively- and negatively-valenced stimuli. The dependent variable is the reaction time index for engagement bias from happy faces. This is calculated as follows: (Cue probe distal to negative image in negative/abstract image pair: RT for target probe distal to negative image minus RT for target probe proximal to negative image) minus (Cue probe distal to neutral image in neutral/abstract image pair: RT for target probe distal to neutral image minus RT for target probe proximal to neutral image). The range of data in our sample was: -237.82 to to 343.93. Statistical analyses have not yet been conducted for this outcome measure.
| milliseconds (ms) | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 9.30 ± 105.87 | 3.29 ± 108.57 |
| Week 5 | -17.65 ± 90.72 | 2.62 ± 96.57 |
| Week 10 | -20.86 ± 69.89 | -22.51 ± 88.93 |
| Week 16 | -22.51 ± 89.93 | 16.36 ± 111.56 |
Heart rate acceleration during presentation of images from the International Affective Picture Systems (IAPS) was used to assess cardiac responding to positive images. The dependent variable is heart rate acceleration during the 6 seconds of positive image presentation relative to the last 2 seconds before picture onset. Higher values indicate greater cardiac responding to positive images. The range of values in our sample was: -0.12 to 0.09.
| beats/ms^2 | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 0.0003 ± 0.0243 | -0.0007 ± 0.0238 |
| Week 5 | -0.0016 ± 0.0222 | -0.0061 ± 0.0331 |
| Week 10 | 0.0071 ± 0.0221 | 0.0013 ± 0.0244 |
| Week 16 | 0.0024 ± 0.0222 | 0.0035 ± 0.0524 |
Mediator: Reported reward consummatory pleasure (score range: 8-48), with higher scores indicating higher reported reward consummatory pleasure
| score on a scale | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 35.81 ± 6.98 | 37.12 ± 6.03 |
| Week 5 | 36.28 ± 6.20 | 37.49 ± 5.83 |
| Week 10 | 37.03 ± 6.17 | 37.97 ± 5.17 |
| Week 16 | 37.70 ± 4.73 | 37.62 ± 5.59 |
The Probabilistic Reward Task (PRT) is a computer-based multi-trial task used to objectively assess the propensity to modulate behavior as a function of prior reinforcements. The dependent variable is response bias (measured as accuracy) toward the more frequently rewarded stimulus. A high response bias emerges when subjects show high rates of correct identification (hits) for the rich stimulus and high miss rates for the lean stimulus (i.e., the stimulus associated with less frequent rewards). Higher values indicate a greater propensity to modulate behavior as a function of prior reinforcements. The range of values in our sample was: -0.58 to 0.78.
| Ratio | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 0.16 ± 0.19 | 0.15 ± 0.29 |
| Week 5 | 0.04 ± 0.27 | 0.19 ± 0.27 |
| Week 10 | 0.09 ± 0.13 | 0.03 ± 0.18 |
| Week 16 | 0.16 ± 0.21 | 0.15 ± 0.23 |
The Pavlovian Instrumental Transfer (PIT) task assesses the extent to which a conditional stimulus paired with reward influences instrumental responding to gain rewards. The dependent variable was handgrip force exerted in response to stimuli during a test phase following Pavlovian conditioning. Higher values indicate greater instrumental responding to gain rewards as a function of Pavlovian conditioning to a conditional stimulus paired with reward. The range of values in our sample was: -18.76 to 61.30.
| volts | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 6.30 ± 12.29 | 4.91 ± 13.54 |
| Week 5 | 7.96 ± 15.61 | 6.72 ± 12.60 |
| Week 10 | 6.55 ± 16.39 | 6.57 ± 12.35 |
| Week 16 | 8.05 ± 16.34 | 1.24 ± 7.96 |
Within the Pavlovian Instrumental Transfer Task (PIT), participants rate the pleasantness (0-4) for three conditional stimuli to indicate the perceived value of reward associated with each one. The dependent variable is the self-reported pleasantness for rewarded stimuli compared to nonrewarded stimuli. This is calculated by first taking the average of participants' pleasantness ratings for the three CS+s and CS-s, and then subtracting the average CS- ratings from the average CS+ ratings. Higher values indicate greater responding to Pavlovian conditioning during the task.
| score on a scale | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Week 0 | 1.09 ± 2.10 | 0.62 ± 2.17 |
| Week 5 | 1.50 ± 2.50 | 0.73 ± 2.99 |
| Week 10 | 1.29 ± 2.88 | 0.44 ± 2.94 |
| Week 16 | 0.74 ± 2.49 | 1.93 ± 1.90 |
Collected over Each participant was assessed over 16 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Positive Affect Treatment | 0/42 (0%) | 0/42 (0%) | 0/42 (0%) |
| Negative Affect Treatment | 0/43 (0%) | 0/43 (0%) | 3/43 (7%) |
| Event | Positive Affect Treatment | Negative Affect Treatment |
|---|---|---|
| Clinical deteriorationPsychiatric disorders | 0/42 | 2/43 |
| Homework noncompliance leading to participant withdrawalPsychiatric disorders | 0/42 | 1/43 |
| Age, Continuous(years) | Positive Affect Treatment | Negative Affect Treatment | Total |
|---|---|---|---|
| Mean | 31.95 ± 11.5 | 31.51 ± 13.1 | 31.73 ± 12.3 |
| Sex: Female, Male(Participants) | Positive Affect Treatment | Negative Affect Treatment | Total |
|---|---|---|---|
| Female | 31 | 36 | 67 |
| Male | 11 | 7 | 18 |
| Race/Ethnicity, Customized(Participants) | Positive Affect Treatment | Negative Affect Treatment | Total |
|---|---|---|---|
| White | 28 | 25 | 53 |
| Asian | 8 | 9 | 17 |
| Alaska Native/Native American/Indigenous | 1 | 0 | 1 |
| Pacific Islander/Native Hawaiian | 0 | 1 | 1 |
| Black or African American | 2 | 3 | 5 |
| Hispanic/Latino (White) | 6 | 9 | 15 |
| Hispanic/Latino (non-White) | 4 | 4 | 8 |
| Multiracial | 3 | 1 | 4 |
| Other | 1 | 7 | 8 |
| Marital status(Participants) | Positive Affect Treatment | Negative Affect Treatment | Total |
|---|---|---|---|
| Married | 9 | 10 | 19 |
| Single, in a relationship | 10 | 13 | 23 |
| Single, not in a relationship | 19 | 19 | 38 |
| Separated | 1 | 1 | 2 |
| Divorced | 3 | 0 | 3 |
| Current psychotropic medication(Participants) | Positive Affect Treatment | Negative Affect Treatment | Total |
|---|---|---|---|
| Count of participants | 12 | 12 | 24 |
| Any diagnosis(Participants) | Positive Affect Treatment | Negative Affect Treatment | Total |
|---|---|---|---|
| Count of participants | 37 | 39 | 76 |
| Depressive diagnoses(Participants) | Positive Affect Treatment | Negative Affect Treatment | Total |
|---|---|---|---|
| Count of participants | 27 | 31 | 58 |
| Major depressive disorder(Participants) | Positive Affect Treatment | Negative Affect Treatment | Total |
|---|---|---|---|
| Count of participants | 19 | 27 | 46 |
11 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2019 to primary completion in Jun 2021, 28 months.
Results were first posted in Dec 2023, 2 years 5 months after primary completion.
Of 3,471 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 28 months is above that.
Counting every sponsor, half of 3,569 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles →